ASCO Conference 2025
We are delighted to be attending the American Society of Clinical Oncology annual conference, May 30 - June 3 2025 in Chicago.
Purdie Pascoe’s experts, Marianne Fillion and Vanessa Slade will be attending the conference, and are looking forward to meeting delegates at the biggest event in Oncology across the globe.
Our dedicated Precision Medicine and Diagnostics team combines extensive scientific knowledge with the ability to navigate both strategic and tactical challenges, ensuring you achieve commercial success and improve human health. We strive to bring you the right answers, to the right questions, at the right time.
Cancer Monitoring US Landscape: ctDNA MRD uptake
Purdie Pascoe is conducting an ongoing ctDNA Cancer Monitoring US Landscape syndicated study. The first two waves are available for purchase, the third wave is being conducted and the results will be available from June 2025.
Gaining a comprehensive understanding of the emerging and evolving ctDNA monitoring landscape is crucial for diagnostics companies in this space, as well as for pharmaceutical companies with product strategies linked to MRD testing. By tracking validated KPIs and market trends, your team can effectively adapt strategies and commercial plans as necessary.
Topics include:
Awareness, Trial and Usage of ctDNA monitoring panels, including newer panels such as xM Tempus, NeXT Personalis and Haystack MRD
Sources of information
Tumour types / stages where ctDNA monitoring is used
Unmet needs, Drivers and Barriers to switch
Perceptions and behaviours toward ctDNA monitoring
To compliment the reports, we've developed an interactive dashboard that makes the data easily digestible, enabling greater segmentation and detailed analysis.
If you are attending ASCO and want to set up a meeting with our experts, or want to learn more about our syndicated study, contact the team using the button below.